Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

NCT05974150 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.

Interventions

  • OTHER Web based survey

Study Locations (7)

Ohio

  • Cleveland Clinic Mercy Hospital — Canton
  • University Hospitals Seidman Cancer Center — Cleveland
  • Tri-County Hematology & Oncology Associates, Inc. — Massillon

North Carolina

  • Univeristy of North Carolina at Chapel Hill — Chapel Hill
  • Duke — Durham

Connecticut

  • Yale Cancer Center — New Haven

Illinois

  • Northshore University Health System — Evanston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2023-07-19
Est. Completion 2026-12-31

Sponsor

Carevive Systems

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05974150

The ClinicalTrials.gov registry entry for NCT05974150 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carevive Systems, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which Web based survey is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05974150 reports 7 study locations spanning 4 distinct geographic areas — top geographies include Ohio, North Carolina, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05974150 about?

NCT05974150 is a clinical study titled "Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring". The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will...

What is the current status of trial NCT05974150?

This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2023-07-19. Estimated completion is 2026-12-31.

What conditions does trial NCT05974150 study?

This clinical trial studies the following conditions: Breast Cancer, Multiple Myeloma, Lung Cancer, Ovarian Cancer, Acute Myelogenous Leukemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05974150?

The interventions under investigation include: Web based survey (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05974150?

This trial is sponsored by Carevive Systems, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05974150 being conducted?

This trial has 7 study locations across Connecticut, Illinois, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial